ALLERGAN LICENSES QUINOLONE ANTIBIOTIC FROM KYORIN.

Allergan, Inc. (NYSE: AGN), Irvine, Calif., and Kyorin Pharmaceutical Co., Ltd. (TSE: 4560), Tokyo, have entered into a license agreement for the development and commercialization of gatifloxacin for the treatment of ocular infections. In conjunction with a license agreement with Kyorin, Bristol Myers Squibb currently commercializes the oral and injectable forms of gatifloxacin, under the brand name Tequin(R), in the United States for the treatment of a broad spectrum of infections, including respiratory and urinary tract infections. The European development and marketing rights for the oral and injectable forms of gatifloxacin were licensed by Grunenthal, a German pharmaceutical company, from Kyorin.

Under the terms of the agreement, Kyorin Pharmaceutical Co., Ltd. will grant Allergan rights to develop and commercialize the topical ophthalmic formulation of gatifloxacin in all territories, except Japan, Korea, China and Taiwan. Kyorin Pharmaceutical Co., Ltd. will receive an upfront payment and additional payments upon the achievement of certain milestones. Kyorin Pharmaceutical Co., Ltd. will also receive royalties on future product sales.

"Allergan is very pleased with the opportunity to enter in to a formal relationship with Kyorin Pharmaceutical Co., Ltd., a company with a well deserved reputation of innovative management and technology," said David E.I. Pyott, president and CEO of Allergan. "The gatifloxacin technology has shown the potential to enhance bactericidal action and decrease the rate of development of resistance in gram-positive bacteria. This technology will further strengthen Allergan's existing portfolio of market leading ocular anti-infectives and will enable the company to better address the medical needs of our customers," continued Pyott.

"It is a great pleasure for Kyorin to have entered into a new business relationship with Allergan, Inc., a worldwide leader in eye care products with respect to both development and marketing activities. In its currently marketed formulations, gatifloxacin effectively acts not only on gram-negative organisms but also on gram-positive organisms with greater anti-microbial activities than those of former quinolone agents. Kyorin is expecting that the development and global introduction of the gatifloxacin ophthalmic topical formulation will be prioritized by Allergan and will be a complement to currently available oral and injectable formulations," said Ikuo Ogihara, president of Kyorin.

Allergan, Inc. headquartered in Irvine, California, is a technology-driven, global health care company providing eye care and specialty pharmaceutical products worldwide. Allergan develops and commercializes products in the eye care pharmaceutical, ophthalmic surgical device, over-the-counter contact lens care, movement disorder, and dermatological markets that deliver value to our customers, satisfy unmet medical needs and improve patients' lives.

Kyorin Pharmaceutical Co., Ltd. is a research-oriented company committed to develop original novel drugs. Kyorin developed the first antibacterial new quinolone (norfloxacin) in the world and established the new antibacterial category called "New Quinolones." Kyorin focuses its scope of marketing segments on respiratory internal medicine, otorhinology and urology.

For more information, visit http://www.kyorin-pharm.co.jp/eng/index2.html. or call 714/246-4515 or visit http://www.allergan.com